Actively Recruiting
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients With Advanced Solid Tumors
Led by CD (Suzhou) Biopharma Co., Ltd. · Updated on 2025-02-07
137
Participants Needed
1
Research Sites
177 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To assess the safety, tolerability, PK and preliminary efficacy of CD-001 in patients with advanced solid tumors. and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
CONDITIONS
Official Title
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older, any gender
- Histologically or cytologically confirmed advanced solid tumors
- Patients lacking standard therapy, progressing after adequate standard therapy, or intolerant of standard therapy
- Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less
- At least one measurable tumor lesion by RECIST v1.1 criteria
- Expected survival of at least 3 months
You will not qualify if you...
- Active central nervous system or leptomeningeal metastases
- Major organ surgery within 4 weeks before first dose or expected major surgery during study
- Severe unhealed wounds, trauma, or ulcers
- Previous major organ, bone marrow, or allogeneic stem-cell transplant
- Active or chronic autoimmune disease requiring systemic therapy within past 2 years or ongoing systemic therapy for autoimmune or inflammatory disease
- Anti-tumor therapy within 4 weeks or 5 drug half-lives before first dose
- Any serious or uncontrollable disease or associated risk as judged by investigator
- History of Grade 3 or higher immune-related adverse events or permanent drug discontinuation due to such events
- Pulmonary embolism within 6 months prior to first dose or presence of interstitial pneumonia at screening
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tianjin Medical University Cancer Institute&Hospital
Tianjin, China
Actively Recruiting
Research Team
D
Daqing Tang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here